Download PDF
1 / Pages

Other users also viewed these articles

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study J.E. Meca-Lallana; J.C. Álvarez-Cermeño; B. Casanova Estruch; G. Izquierdo Ayuso; R. Ortiz Castillo; A. Rodríguez-Antigüedad; C. Calles Hernández;
Neurologia. 2024;39:383-91
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023 J.E. Meca-Lallana; S. Martínez Yélamos; S. Eichau; M.Á. Llaneza; J. Martín Martínez; J. Peña Martínez; V. Meca Lallana; A.M. Alonso Torres; E. Moral Torres; J. Río; C. Calles; A. Ares Luque; L. Ramió-Torrentà; M.E. Marzo Sola; J.M. Prieto; M.L. Martínez Ginés; R. Arroyo; M.Á. Otano Martínez; L. Brieva Ruiz; M. Gómez Gutiérrez; A. Rodríguez-Antigüedad Zarranz; V.G. Sánchez-Seco; L. Costa-Frossard; M.Á. Hernández Pérez; L. Landete Pascual; M. González Platas; C. Oreja-Guevara;
Neurologia. 2024;39:196-208
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the ¿no evidence of disease activity¿ parameter A. Pato Pato; E. Costa Arpín; A. Rodríguez Regal; I. Rodríguez Constenla; I. Cimas Hernando; I. Muñoz Pousa; L. Naya Ríos; J.R. Lorenzo González; M.C. Amigo Jorrín; J.M. Prieto González;
Neurologia. 2021;36:346-52